lifestyle.pspl.com

Author: PulseSight Therapeutics S.A.S

Positive Results from PulseSight’s Phase I Clinical Trial of PST-611 in Dry AMD/Geographic Atrophy Presented at ARVO 2026

May 11, 2026
Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

May 5, 2026
Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

January 25, 2026